

Bal Pharma Limited

14.12.2022

To,
The Manager-Listing
BSE Limited
Mumbai.

To
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub: Proceedings of Extra Ordinary General Meeting ('EGM') of the

Company held on 14.12.2022.

Ref : Scrip code 524824 for BSE and BALPHARMA for NSE.

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting to the exchange the business transacted at the Extra Ordinary General Meeting of the Company conducted through audio visual means, on 14.12.2022.

Mr.Shailesh Siroya was elected as Chairman and he chaired the proceedings of the meeting with requisite quorum.

Special Business:

 To seek the consent of the members for filing an application under Section 230(1) of the Companies Act, 2013 with National Company Law Tribunal, Bengaluru Bench in connection with proposed merger of Wholly Owned Subsidiary Company i.e Golden Drugs Private Limited (Transferor Company) with Bal Pharma Limited (Transferee Company).

Chairman invited questions and queries from the members present at the meeting and the same were suitably answered.

Mr.Jose Thomas, Practising Company Secretary was appointed as the scrutinizer for the e-voting and the results of e-voting will be announced after receipt of Scrutinizer's Report. The e-voting results will also be submitted to the exchanges as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and be uploaded on our website.

Digitally signed by 94ALESH SBDYA
Discrist, postalCoder/SDD202, smEARNATAKA,
street-BANGALORE, InBANGALORE, on-Personal,
smithtenbern of 38Abb66(s)35e 382472.699 S8c 18525144997
for 3224076(s)25b0 10006c5,
preudonym r03rd385569946abberd3b16569946526.

SIROYA

CORPORATE OFFICE: 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph.: 91 - 80 - 41379500 Fax: 91 - 80 - 22354057 / 58 Email: info@balpharma.com Website: www.balpharma.com



Page-2

The Extra Ordinary General Meeting commenced at 11.30 AM as scheduled and concluded at 12.15 PM on 14.12.2022.

Please take this intimation on record.

Thanking you

For Bal Pharma Limited

SHAILES

Depubling sub-by season at 100 cm.

SHAILES

Depubling sub-by season at 100 cm.

Depubling su

Shailesh Siroya Managing Director.